Stock Research for GHDX


Featured Broker: Ally Invest

Get the due diligence for another stock.


GHDX Stock Chart & Research Data

The GHDX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the GHDX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


GHDX Due diligence Resources & Stock Charts

The GHDX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View GHDX Detailed Price Forecast - CNN Money CNN View GHDX Detailed Summary - Google Finance
Yahoo View GHDX Detailed Summary - Yahoo! Finance Zacks View GHDX Stock Research & Analysis -

Stock Analysis

TradeIdeas View GHDX Trends & Analysis - Trade-Ideas Barrons View GHDX Major Holders - Barrons
NASDAQ View GHDX Call Transcripts - NASDAQ Seeking View GHDX Breaking News & Analysis - Seeking Alpha
Spotlight View GHDX Annual Report - OTC Report View GHDX OTC Short Report -
TradeKing View GHDX Fundamentals - TradeKing Charts View GHDX SEC Filings - Bar Chart
WSJ View Historical Prices for GHDX - The WSJ Morningstar View Performance/Total Return for GHDX - Morningstar
MarketWatch View the Analyst Estimates for GHDX - MarketWatch CNBC View the Earnings History for GHDX - CNBC
StockMarketWatch View the GHDX Earnings - StockMarketWatch MacroAxis View GHDX Buy or Sell Recommendations - MacroAxis
Bullish View the GHDX Bullish Patterns - American Bulls Short Pains View GHDX Short Pain Metrics -

Social Media Mentions

StockTwits View GHDX Stock Mentions - StockTwits PennyStocks View GHDX Stock Mentions - PennyStockTweets
Twitter View GHDX Stock Mentions - Twitter Invest Hub View GHDX Investment Forum News - Investor Hub
Yahoo View GHDX Stock Mentions - Yahoo! Message Board Seeking Alpha View GHDX Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for GHDX - Insider Cow View Insider Transactions for GHDX - Insider Cow
CNBC View GHDX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for GHDX - OTC Markets
Yahoo View Insider Transactions for GHDX - Yahoo! Finance NASDAQ View Institutional Holdings for GHDX - NASDAQ

Stock Charts

FinViz View GHDX Stock Insight & Charts - StockCharts View GHDX Investment Charts -
BarChart View GHDX Stock Overview & Charts - BarChart Trading View View GHDX User Generated Charts - Trading View

Latest Financial News for GHDX

Why Is Genomic Health (GHDX) Up 1.6% Since Its Last Earnings Report?
Posted on Monday April 09, 2018

Genomic Health (GHDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Intrinsic Calculation For Genomic Health Inc (NASDAQ:GHDX) Shows Investors Are Overpaying
Posted on Friday March 30, 2018

How far off is Genomic Health Inc (NASDAQ:GHDX) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stock isRead More...

Epic Sciences and Genomic Health Announce Favorable Draft Local Coverage Determination (LCD) on Medicare Coverage for Use of the Oncotype DX® AR-V7 Nucleus Detect™ Test in Patients with Metastatic Castration-Resistant Prostate Cancer
Posted on Friday March 30, 2018

Medicare Draft Coverage Supports Clinical Utility of the Oncotype DX AR-V7 Nucleus Detect Test, Providing 25,000 Medicare Patients with Coverage Once LCD Is Finalized SAN DIEGO and REDWOOD CITY, Calif. ...

Landmark TAILORx Results Aid in Assessing the Effect of Chemotherapy in Women with Early-stage Breast Cancer and Oncotype DX Breast Recurrence Score® Results of 11 to 25
Posted on Thursday March 15, 2018

REDWOOD CITY, Calif., March 15, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) was informed by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) that the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, has achieved sufficient information to render a conclusion regarding the effect of chemotherapy in early-stage breast cancer patients with Recurrence Score® results of 11 to 25.  This primary study group represents approximately 100,000 women diagnosed each year in the United States alone. ECOG-ACRIN will be submitting the results as a late-breaking abstract for presentation at an upcoming major medical meeting. The TAILORx trial was independently designed and conducted by ECOG-ACRIN under the sponsorship of the National Cancer Institute (NCI), part of the National Institutes of Health.

Enter a stock symbol to view the stock details.